X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
The net proceeds will be used for the clinical development of CGT9486 (bezuclastinib), which is a KIT mutant inhibitor for patients living with systemic mastocytosis and gastrointestinal stromal tumors.
Lead Product(s): Bezuclastinib,Sunitinib
Therapeutic Area: Oncology Product Name: CGT9486
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $225.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement February 14, 2024
Details:
Cogent intends to fund the development, regulatory and commercial preparation activities relating to CGT9486 (bezuclastinib), a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17.
Lead Product(s): Bezuclastinib,Sunitinib
Therapeutic Area: Oncology Product Name: CGT9486
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $150.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 06, 2023
Details:
Cabometyx (cabozantinib) is a multiple receptor tyrosine kinases inhibitor. These receptors are involved in both normal cellular function and pathologic processes such as oncogenesis, metastasis, tumor angiogenesis, maintenance of the tumor microenvironment, etc.
Lead Product(s): Cabozantinib,Nivolumab,Sunitinib
Therapeutic Area: Oncology Product Name: Cabometyx
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 13, 2023
Details:
The net proceeds from the offering will be used for development, regulatory and commercial preparation activities relating to CGT9486 (bezuclastinib) and other product candidates, as well as for working capital and general corporate purposes.
Lead Product(s): Bezuclastinib,Sunitinib
Therapeutic Area: Oncology Product Name: CGT9486
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Jefferies
Deal Size: $172.6 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 16, 2022
Details:
Cogent intends to use the net proceeds from the offering for development, regulatory and commercial preparation activities relating to CGT9486 (bezuclastinib) and other product candidates, as well as for working capital and general corporate purposes.
Lead Product(s): Bezuclastinib,Sunitinib
Therapeutic Area: Oncology Product Name: CGT9486
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Jefferies
Deal Size: $150.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 14, 2022
Details:
Updated outcomes from trial evaluating combination of Cabometyx (Cabozantinib) plus atezolizumab in an expanded patient population in NSCLC demonstrate encouraging clinical activity with manageable toxicity in people previously treated with an immune checkpoint inhibitor.
Lead Product(s): Cabozantinib,Nivolumab,Sunitinib
Therapeutic Area: Oncology Product Name: Cabometyx
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2022
Details:
GB-102 is a microparticle formulation of a pan-VEGF inhibitor, sunitinib, for the treatment of wet age-related macular degeneration designed for a twice-per-year intravitreal injection. GB-102 has the potential to also benefit patients with diabetic retinopathy.
Lead Product(s): Sunitinib
Therapeutic Area: Ophthalmology Product Name: GB-102
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 19, 2022
Details:
The MERECA study showed that the combination of ilixadencel with the tyrosine kinase inhibitor sunitinib was safe and associated with a positive trend for improved tumor response rate and overall survival, compared with sunitinib monotherapy (control group).
Lead Product(s): Ilixadencel,Sunitinib
Therapeutic Area: Oncology Product Name: Intuvax
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 28, 2022
Details:
Phase 2 study investigating CGT9486 for the treatment of patients with Advanced Systemic Mastocytosis (AdvSM), including patients with Aggressive SM (ASM), SM with Associated Hematologic Neoplasm (SM-AHN), and Mast Cell Leukemia (MCL).
Lead Product(s): Bezuclastinib,Sunitinib
Therapeutic Area: Oncology Product Name: CGT9486
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2022
Details:
GB-102, a formulation of the pan-vascular endothelial growth factor (VEGF) inhibitor, sunitinib malate targeting a six-month or longer dosing regimen used for the treatment of wet age-related macular degeneration (wet AMD).
Lead Product(s): Sunitinib
Therapeutic Area: Ophthalmology Product Name: GB-102
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2021
Details:
The ALTISSIMO trial is a masked and controlled Phase 2b dose-ranging study of two doses of GB-102 with a single control arm of patients on aflibercept. 48% of patients in the GB-102 1 mg arm were rescue-free for at least 6 months.
Lead Product(s): Sunitinib
Therapeutic Area: Ophthalmology Product Name: GB-102
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 09, 2021
Details:
Sunitinib is an oral multi-kinase inhibitor (MKI), works by blocking several enzymes that promote cell growth. It is useful for the treatment of certain patients with gastrointestinal stromal tumors and advanced renal cell carcinoma.
Lead Product(s): Sunitinib
Therapeutic Area: Oncology Product Name: Sutib
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 16, 2021
Details:
Graybug’s lead product candidate, GB-102, is a proprietary microparticle depot formulation of the pan-vascular endothelial growth factor (pan-VEGF) inhibitor, sunitinib malate, designed to be administered intravitreally twice per year.
Lead Product(s): Sunitinib
Therapeutic Area: Ophthalmology Product Name: GB-102
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 07, 2021
Details:
Based on the updated survival data, the final median OS value was reached in the sunitinib control group, while the median OS has not yet been reached in the ilixadencel treatment group.
Lead Product(s): Ilixadencel,Sunitinib
Therapeutic Area: Oncology Product Name: Intuvax
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 18, 2020
Details:
Acquisition includes lead clinical-stage compound PLX9486, a potent and selective KIT D816V inhibitor.
Lead Product(s): Bezuclastinib,Sunitinib
Therapeutic Area: Oncology Product Name: PLX9486
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Unum Therapeutics
Deal Size: $104.4 million Upfront Cash: Undisclosed
Deal Type: Acquisition July 06, 2020
Details:
A limited interim safety analysis performed in February 2020 supports Graybug’s intention to take the 1 mg dose forward for further exploration in clinical trials.
Lead Product(s): Sunitinib
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 18, 2020
Details:
Survival as of December 2019 was 54% in the ilixadencel treatment group compared with 37% of patients in the control group treated with sunitinib monotherapy.
Lead Product(s): Ilixadencel,Sunitinib
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 06, 2020
Details:
The MERECA trial investigated Immunicum’s lead product, ilixadencel, in combination with Sutent® (sunitinib) as a first-line treatment in patients with metastatic kidney cancer.
Lead Product(s): Ilixadencel,Sunitinib
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 03, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
